With the COVID-19 pandemic nearing its second year in the U.S., lawmakers have banged the drum on boosting “onshore” production of key pharmaceuticals and ingredients to ensure supply-side security. Now, a New Jersey-based contract manufacturer is dropping more money into its Iowa site to support the effort.
Cambrex will invest $50 million to add four active pharmaceutical ingredients (API) facilities at its Charles City, Iowa small-molecule drug site and expand capacity by 30%, the company said Tuesday.
The new facilities—three of which will handle “large-scale” manufacturing, with the fourth dedicated to “mid-scale” production—are set to go online in early 2022, Cambrex said in a release. In total, the Charles City site will eventually employ 400 workers.
The Rise of HPAPI Molecules – Trends in Highly Potent API Manufacturing
Highly potent active pharmaceutical ingredients are increasing in pharma pipelines. Lonza offers all HPAPI-related expertise to support your product development from concept to commercial use in an integrated manner.
The $50 million down payment is the sixth investment round Cambrex has made in Charles City in the last eight years, the company said, and it continues the CDMO’s play at offering stateside API production to drugmakers looking for a “reliable” supply chain.
We help you with global pharma industry news aggregated from leading global media, insights, useful skill development tool kit, a powerful experience-sharing platform & much more. Personal & family health is paramount so to help you in this regard, we also offer some of the finest fitness articles posted globally. PHARMABOX.IN is specifically designed to be a one-stop solution for pharma professionals. Do follow us on social media to be abreast with the latest development.